FinnRick Verification Reveals 85% Purity Gap in Custom Peptide Synthesis: A Data-Driven Industry Benchmarking Study
Abstract: FinnRick Verification’s benchmarking study reveals an 85% purity gap in custom peptide synthesis, underscoring critical quality disparities across brands. Analyzing 500+ samples, data shows only 12% of suppliers meet ≥98% purity standards, while 73% fall below 95%. This impacts therapeutic efficacy and research reproducibility. The study compares leading brands (e.g., Bachem, GenScript) on purity, yield, and certification (ISO 9001, GMP). Market trends indicate a shift toward high-purity peptides for clinical applications, demanding rigorous supplier audits. Key selection criteria include third-party COAs, batch consistency, and logistics (cold-chain compliance). Industry consolidation favors certified manufacturers, with 68% of buyers prioritizing purity over cost. The findings establish a data-driven benchmark for peptide sourcing, emphasizing transparency and regulatory adherence.